New and upcoming MIGS with Shan Lin, MD

Sean Lin, MD, is the co-research director at the Glaucoma Center of San Francisco. At the Glaucoma 360 meeting, he discussed the new generation of minimally invasive glaucoma surgeries (MIGS).

Lin expresses excitement about the recent advancements in MIGS, with some already approved and others soon to be approved. He highlights several new categories of MIGs, including trabecular procedures. Lin also discusses suprachoroidal stents that lower intraocular pressure by placing a stent in the suprachoroidal space. Sclera-based procedures are another area of progress.

He emphasizes that the field of MiGs is undergoing continuous evolutionary development, with five or six new procedures either approved or soon to be. He believes this represents significant progress in glaucoma surgery. The conversation then shifts to the potential for neuroprotective agents in glaucoma treatment.

Lin also shared his experience as a principal investigator for an earlier neuroprotective trial that, while not successful in its endpoints, did lay the foundation for the future advancements that he hopes will come in this area of research and treatment. He expressed optimism that the field is on the cusp of advancements in this area and could make significant progress in the coming years to better serve patients with not only thier vision, but also their quality of life.

Overall, the conversation with Lin provides an overview of the exciting new developments in minimally invasive glaucoma surgeries and the promising outlook for neuroprotective treatments in glaucoma care.